According to MannKind Corporation, Brazil's Drug Market Regulation Chamber (CMED) has approved the proposed pricing for Afrezza inhaled insulin, and the Afrezza DPI is set to launch in Brazil within the next week. The Brazilian Health Regulatory Agency (ANVISA) approved Afrezza for the treatment of diabetes in June 2019. In June 2017, MannKind announced that it … [Read more...] about Afrezza to be launched in Brazil
Business
Impopharma acquired by Rubicon Research
Canadian CRO Impopharma, which specializes in OINDP analysis and development, has been acquired by Rubicon Research, Rubicon said. Impopharma's Concord, ON facility will become Rubicon's Nasal and Pulmonary Center of Excellence. Impopharma's services included testing and development of nasal sprays, MDIs, and DPIs. According to Rubicon, the company expects the … [Read more...] about Impopharma acquired by Rubicon Research
Pulmatrix announces collaboration with Nocion Therapeutics
Two months after announcing the appointment of Nocion Therapeutics CEO Rick Batycky to its board, Pulmatrix has announced a deal with Nocion to look at the use of Pulmatrix's iSPERSE particle engineering technology for development of inhaled formulations of Nocion drugs. According to the Nocion web site, the company's lead candidate targets refractory chronic cough. … [Read more...] about Pulmatrix announces collaboration with Nocion Therapeutics
ATAI Life Sciences partners with Neuronasal on intranasal N-acetylcysteine for concussion
ATAI Life Sciences has announced a deal with US-based Neuronasal Inc. for development of intranasal N-acetylcysteine (NAC) for the treatment of mild traumatic brain injury (mTBI, or concussion). ATAI said that it expects initiation of a pilot study in healthy volunteers in February 2020. According to a Neuronasal presentation, the drug would be delivered via the … [Read more...] about ATAI Life Sciences partners with Neuronasal on intranasal N-acetylcysteine for concussion
Pulmatrix announces license agreement with J&J’s Lung Cancer Initiative
According to Pulmatrix, the Lung Cancer Initiative at Johnson & Johnson will pay $7.2 million up front plus a $2 million milestone payment for an option "to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception." The $2 million milestone payment will be due on completion of a Phase 1b study of RV1162/PUR1800 … [Read more...] about Pulmatrix announces license agreement with J&J’s Lung Cancer Initiative
CF PharmTech gets $90 million in latest financing round for inhaled drug development
CF PharmTech, which says it is developing a variety of OINDPs, announced that it has closed a Series E financing round that will be used to support development of its pipeline products. The $90 million round was led by Shanghai-based New Alliance Capital. In August 2017, the company said that it had raised $65 million in a Series D round to support development … [Read more...] about CF PharmTech gets $90 million in latest financing round for inhaled drug development
Savara announces $26.8 million private placement
Inhaled drug developer Savara announced that it has entered into a definitive agreement for a private placement of common stock, pre-funded warrants, and milestone warrants with an expected $26.8 million in gross proceeds from sales of the common stock and pre-funded warrants and a potential of up to $75 million if all milestone warrants are exercised. The private … [Read more...] about Savara announces $26.8 million private placement
3M Drug Delivery Systems sold to Altaris Capital Partners
3M has announced the sale of "substantially all" of 3M Drug Delivery Systems to Altaris Capital Partners for approximately $650 million. 3M will keep a 17% interest in the new business, which is expected to employ approximately 900 of the current employees after the sale is completed. 3M's inhalation products include standard MDIs, a nasal MDI, and the Intelligent … [Read more...] about 3M Drug Delivery Systems sold to Altaris Capital Partners
Windtree Therapeutics announces completion of $26.4 million private placement
Aerosurf inhaled surfactant developer Windtree Therapeutics has announced the completion of a $26.4 million private placement of common stock and warrants. Net proceeds were approximately $23 million. Windtree is developing several inhaled drugs delivered via the company's proprietary Aerosol Delivery System (ADS). In addition to Aerosurf inhaled KL4 surfactant, … [Read more...] about Windtree Therapeutics announces completion of $26.4 million private placement
Chiesi announces plans for lower carbon footprint HFA 152a inhaler by the end of 2025
Chiesi announced that the company has signed an agreement with Koura (formerly Mexichem) for supply of HFA 152a propellant as part of a €350 million plan to bring a pMDI with a 90% lower carbon footprint to market by the end of 2025. The company, which has also pledged that it would be carbon neutral by 2035, made the announcement at the Nations Climate Change … [Read more...] about Chiesi announces plans for lower carbon footprint HFA 152a inhaler by the end of 2025